Complix
Developing a pipeline of transformative Cell Penetrating Alphabody™ (CPAB) based oncology therapeutics.
Launch date
Employees
Market cap
-
Enterprise valuation
€48—72m (Dealroom.co estimates Jun 2013.)
Company register number 0898.945.025
Ghent East Flanders (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Profit | (1.7m) | (2.0m) | (1.0m) | (<1m) |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
| N/A | $6.2m | Series A | |
€2.0m | Series A | ||
€12.0m | Series B | ||
N/A | Grant | ||
* | €500k | Grant | |
€1.2m | Grant | ||
| Total Funding | €21.3m | ||
Recent News about Complix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.